SEC Form SC 13G filed by Day One Biopharmaceuticals Inc.

11/7/24 9:12:22 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $DAWN alert in real time by email

SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 DAY ONE BIOPHARMACEUTICALS INC COMMON STOCK Cusip #23954D109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #23954D109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 7,389,000 Item 6: 0 Item 7: 7,412,380 Item 8: 0 Item 9: 7,412,380 Item 11: 7.539% Item 12: HC Cusip #23954D109 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 7,412,380 Item 8: 0 Item 9: 7,412,380 Item 11: 7.539% Item 12: IN Item 1(a). Name of Issuer: DAY ONE BIOPHARMACEUTICALS INC Item 1(b). Address of Issuer's Principal Executive Offices: 2000 SIERRA POINT PARKWAY, SUITE 501 Brisbane, CA 94005 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 23954D109 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 7,412,380 (b) Percent of Class: 7.539% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 7,412,380 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of DAY ONE BIOPHARMACEUTICALS INC. No one other person's interest in the COMMON STOCK of DAY ONE BIOPHARMACEUTICALS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 6, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 6, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of DAY ONE BIOPHARMACEUTICALS INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $DAWN alert in real time by email

Recent Analyst Ratings for

$DAWN

Date	Price Target	Rating	Analyst
10/9/2024	$32.00 → $33.00	Buy	Needham
8/1/2024	$11.00 → $24.00	Underperform → Buy	BofA Securities
4/24/2024	$30.00 → $33.00	Buy	Needham
4/25/2023	$34.00 → $9.00	Buy → Underperform	BofA Securities
2/8/2023	$40.00	Overweight	CapitalOne
2/3/2023		Perform	Oppenheimer
12/15/2022	$35.00	Buy	H.C. Wainwright
12/14/2022	$40.00	Buy	Needham

More analyst ratings

SEC Form SC 13G filed by Day One Biopharmaceuticals Inc.

Chat with this insight

Recent Analyst Ratings for $DAWN

$DAWN FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

April 30, 2024 - FDA Roundup: April 30, 2024

April 26, 2024 - FDA Roundup: April 26, 2024

FDA Approval for OJEMDA issued to DAY ONE BIOPHARMACEUTICALS INC

$DAWN Financials

Live finance-specific insights

Day One Reports Third Quarter 2024 Financial Results and Corporate Progress

Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024

Day One Reports Second Quarter 2024 Financial Results and Corporate Progress

$DAWN Market Insights

Live Market Insights

$DAWN Leadership Updates

Live Leadership Updates

$DAWN Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Ipsen And Day One Earlier Announced Exclusive Ex U.S. Licensing Agreement To Commercialize Tovorafenib For The Most Common Childhood Brain Tumor

Ipsen And Day One Enter Ex-U.S. Licensing Deal For Pediatric Brain Cancer Drug Tovorafenib

Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development

Day One Announces Two New Appointments to Board of Directors

Day One Appoints Garry Nicholson as Chairman of the Board of Directors

CHIEF EXECUTIVE OFFICER Bender Jeremy sold $139,420 worth of shares (10,554 units at $13.21) and converted options into 19,999 shares, increasing direct ownership by 10% to 108,377 units (SEC Form 4)

HEAD OF R&D Blackman Samuel C. converted options into 8,686 shares and sold $29,142 worth of shares (2,206 units at $13.21), increasing direct ownership by 0.61% to 1,064,015 units (SEC Form 4)

GENERAL COUNSEL Dubow Adam converted options into 8,399 shares and sold $41,810 worth of shares (3,165 units at $13.21), increasing direct ownership by 19% to 32,162 units (SEC Form 4)

$DAWN Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Needham reiterated coverage on Day One Biopharmaceuticals with a new price target

Day One Biopharmaceuticals upgraded by BofA Securities with a new price target

Needham reiterated coverage on Day One Biopharmaceuticals with a new price target

$DAWN Large Ownership Changes

This live feed shows all institutional transactions in real time.

$DAWN Press Releases

Fastest customizable press release news feed in the world

Amendment: SEC Form SC 13G/A filed by Day One Biopharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Day One Biopharmaceuticals Inc.